Profile
| Role | Insider |
|---|---|
| Notability | 30/100 |
Board memberships
- Liquidia Corp
- Candel Therapeutics, Inc.
- Verrica Pharmaceuticals Inc.
Updated Jul 16, 2026
Manning Paul B has filed 4 SEC Form 4 filings across 2 companies in the last 90 days — active on both sides. Lifetime open-market purchases: $10.50M. Lifetime open-market sales: $31.74M. Historical track record: 5/5 stars across 3 tracked purchases.
| Role | Insider |
|---|---|
| Notability | 30/100 |
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.
| InsiderAlpha rating | ★★★★★ (5/5) |
|---|---|
| Total purchases tracked | 3 |
| Purchases with forward-return data | 3 |
| 30-day win rate | 10000% |
| 90-day win rate | 10000% |
| Avg 5-day return | +2774.64% |
| Avg 30-day return | +2011.79% |
| Avg 90-day return | +4896.03% |
| Best 30-day return | +2997.56% |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-18 | LQDA | Liquidia Corp | A — Grant or award | 5.9K | $0.00 | |
| 2026-06-08 | LQDA | Liquidia Corp | S — Open-market sale | 12.6K | $64.42 | $812K |
| 2026-06-08 | LQDA | Liquidia Corp | S — Open-market sale | 68.3K | $63.83 | $4.36M |
| 2026-06-08 | LQDA | Liquidia Corp | S — Open-market sale | 19.1K | $62.62 | $1.20M |
| 2026-06-08 | LQDA | Liquidia Corp | S — Open-market sale | 88.5K | $64.28 | $5.69M |
| 2026-06-08 | LQDA | Liquidia Corp | S — Open-market sale | 11.5K | $63.13 | $727K |
| 2026-02-27 | CADL | Candel Therapeutics, Inc. | P — Open-market purchase | 550.5K | $5.45 | $3.00M |
| 2026-02-13 | LQDA | Liquidia Corp | J — Other acquisition / disposition | 55.1K | $42.63 | $2.35M |
| 2026-02-13 | LQDA | Liquidia Corp | J — Other acquisition / disposition | 55.1K | $42.63 | $2.35M |
| 2025-08-28 | LQDA | Liquidia Corp | S — Open-market sale | 74.2K | $29.14 | $2.16M |
| 2025-08-28 | LQDA | Liquidia Corp | S — Open-market sale | 254.0K | $28.67 | $7.28M |
| 2025-08-28 | LQDA | Liquidia Corp | S — Open-market sale | 188.2K | $27.62 | $5.20M |
| 2025-08-28 | LQDA | Liquidia Corp | S — Open-market sale | 154.3K | $27.94 | $4.31M |
| 2024-12-18 | CADL | Candel Therapeutics, Inc. | P — Open-market purchase | 750.0K | $6.00 | $4.50M |
| 2024-12-18 | CADL | Candel Therapeutics, Inc. | P — Open-market purchase | 500.0K | $6.00 | $3.00M |
| 2024-11-26 | VRCA | Verrica Pharmaceuticals Inc. | G — Bona-fide gift | 450.0K | $0.00 | |
| 2024-11-26 | VRCA | Verrica Pharmaceuticals Inc. | P — Open-market purchase | 4.49M | — | |
| 2024-11-26 | VRCA | Verrica Pharmaceuticals Inc. | P — Open-market purchase | 18.43M | — |
Manning Paul B is a corporate insider — currently tracked as Insider of Candel Therapeutics, Inc. (CADL). InsiderAlpha tracks every SEC Form 4 filing in real time.
4 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 9 open-market purchases ($10.50M) and 9 open-market sales ($31.74M) across all tracked filings.
Across 3 tracked purchases, Manning Paul B averaged +2011.8% avg 30-day return with a 10000% 30-day win rate. InsiderAlpha rates the track record at 5/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Manning Paul B profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.